Form 8-K - Current report:
SEC Accession No. 0001562762-22-000140
Filing Date
2022-03-28
Accepted
2022-03-28 15:50:55
Documents
14
Period of Report
2022-03-24
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 20220317_8k.htm   iXBRL 8-K 23254
2 exhibit991.htm EX-99.1 66360
3 exhibit991p1i0.jpg GRAPHIC 1738
  Complete submission text file 0001562762-22-000140.txt   224513

Data Files

Seq Description Document Type Size
4 vaxx-20220324.xsd EX-101.SCH 1794
5 vaxx-20220324_lab.xml EX-101.LAB 12730
6 vaxx-20220324_pre.xml EX-101.PRE 13612
8 EXTRACTED XBRL INSTANCE DOCUMENT 20220317_8k_htm.xml XML 4319
Mailing Address 1717 MAIN STREET SUITE 3388 DALLAS TX 75201
Business Address 1717 MAIN STREET SUITE 3388 DALLAS TX 75201 (254) 244-5739
Vaxxinity, Inc. (Filer) CIK: 0001851657 (see all company filings)

IRS No.: 862083865 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41058 | Film No.: 22775340
SIC: 2834 Pharmaceutical Preparations